Quoin Pharmaceuticals reports Q2 EPS ($1.90) vs FactSet ($1.61) [4 est, ($1.93)-(1.07)] ($6.05, 0.00)
Quoin Pharmaceuticals receives FDA IND clearance to initiate Phase 2 study of QRX003 in peeling skin syndrome ($4.72, 0.00)
Quoin Pharmaceuticals receives U.S. notice of allowance for patent covering combination treatment for Netherton syndrome ($4.55, 0.00)
Quoin Pharmaceuticals receives FDA conditional approval of QYLEKI as the proposed brand name for QRX003 for Netherton syndrome ($4.41, 0.00)
Quoin Pharmaceuticals completes establishment of Japanese subsidiary to advance commercial readiness for QRX003 ($4.62, 0.00)
Quoin Pharmaceuticals provides clinical update from ongoing Pediatric Netherton Syndrome Compassionate Use Program ($4.65, 0.00)
ThinkEquity initiates GLND, QNRX
StreetAccount Summary: Notable Drug Events expected for the week of 14-June
StreetAccount Summary: Notable Drug Events expected for the week of 7-June
Quoin Pharmaceuticals announces Japan's MHLW grants orphan drug designation for QRX003 in Netherton syndrome ($4.43, 0.00)
Powered by FactSet Research Systems Inc.